SCHEMBL3553748

SCHEMBL3553748

CCCC(=O)Nc1ccccc1CCCCCc1ccccc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 10/20 0.65
MAPK1 P28482 1/20 0.51
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3555542 0.89 SLC16A3 (0.68) SLC16A3NPC1ALDH1A1RAB9AKMT2A
SCHEMBL3555106 0.88 SLC16A3 (0.63) SLC16A3NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3558553 0.87 SLC16A3 (0.62) SLC16A3NPC1RAB9ASMN1; SMN2
SCHEMBL3556047 0.87 SLC16A3 (0.62) SLC16A3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3554353 0.85 SLC16A3 (0.66) SLC16A3MEN1ALDH1A1LMNAKMT2A
SCHEMBL3561577 0.85 SLC16A3 (0.66) SLC16A3MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL3560444 0.83 SLC16A3 (0.64) SLC16A3HDAC3HDAC4HDAC1HDAC7
SCHEMBL3556472 0.83 SLC16A3 (0.64) SLC16A3ALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL3557628 0.83 SLC16A3 (0.64) SLC16A3ALDH1A1KMT2A
SCHEMBL3554088 0.83 SLC16A3 (0.63) SLC16A3MEN1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885MAPK1 667/4885HDAC3 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.